{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:30:30Z","timestamp":1791909030873,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40262-015-0285-z","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T01:47:58Z","timestamp":1433382478000},"page":"1027-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Clinical Pharmacokinetic, Pharmacodynamic, and Drug\u2013Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor"],"prefix":"10.1007","volume":"54","author":[{"given":"Damayanthi","family":"Devineni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,4]]},"reference":[{"key":"285_CR1","doi-asserted-by":"crossref","unstructured":"American-Diabetes-Association. Standards of medical care in diabetes\u20142015. Diabetes Care. 2015; 38 Suppl 1: S11\u201366.","DOI":"10.2337\/dc15-S003"},{"issue":"5","key":"285_CR2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1742-1241.2012.02894.x","volume":"66","author":"MF Braga","year":"2012","unstructured":"Braga MF, Casanova A, Teoh H, Gerstein HC, Fitchett DH, Honos G, et al. Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract. 2012;66(5):457\u201364.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"285_CR3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/2047487312449414","volume":"20","author":"MP Hermans","year":"2013","unstructured":"Hermans MP, Brotons C, Elisaf M, Michel G, Muls E, Nobels F. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol. 2013;20(6):1095\u2013105.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"285_CR4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1479164112436403","volume":"9","author":"ND Wong","year":"2012","unstructured":"Wong ND, Glovaci D, Wong K, Malik S, Franklin SS, Wygant G, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res. 2012;9(2):146\u201352.","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"285_CR5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733\u201394.","journal-title":"Physiol Rev"},{"issue":"4","key":"285_CR6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-013-0128-8","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(4):295\u2013304.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"285_CR7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/156802610790980567","volume":"10","author":"S Nomura","year":"2010","unstructured":"Nomura S. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. Curr Top Med Chem. 2010;10(4):411\u20138.","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"285_CR8","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7(2):e30555.","journal-title":"PLoS One"},{"issue":"5","key":"285_CR9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W Meng","year":"2008","unstructured":"Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145\u20139.","journal-title":"J Med Chem"},{"issue":"1","key":"285_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"285_CR11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","volume":"53","author":"D Devineni","year":"2013","unstructured":"Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53(6):601\u201310.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"285_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CP202218","volume":"53","author":"D Devineni","year":"2015","unstructured":"Devineni D, Vaccaro N, Polidori D, Stieltjes H, Wajs E. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int J Clin Pharmacol Ther. 2015;53(2):129\u201338.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"285_CR13","author":"D Devineni","year":"2014","unstructured":"Devineni D, Manitpisitkul P, Murphy J, Skee D, Wajs E, Mamidi RN, et al. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin and simvastatin in healthy participants. Clin Pharm Drug Dev. 2014;. doi: 10.1002\/cpdd.166 .","journal-title":"Clin Pharm Drug Dev"},{"issue":"1","key":"285_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5414\/CP202157","volume":"53","author":"D Devineni","year":"2015","unstructured":"Devineni D, Manitpisitkul P, Vaccaro N, Bernard A, Skee D, MamidiRao N, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants. Int J Clin Pharmacol Ther. 2015;53(1):41\u201353.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"285_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202158","volume":"53","author":"D Devineni","year":"2015","unstructured":"Devineni D, Vaccaro N, Murphy J, Curtin C, MamidiRao N, Weiner S, et al. Effects of rifampin, cyclosporine A, or probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015;53(2):115\u201328.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"285_CR16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","volume":"36","author":"D Devineni","year":"2014","unstructured":"Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014;36(5):698\u2013710.","journal-title":"Clin Ther"},{"key":"285_CR17","unstructured":"Wexler D, Vandebosch A, Usiskin K, Allison M, Devineni D. Study of electrocardiogram intervals in healthy adults receiving single oral doses of canagliflozin. Diabetes. 2010;59(1)."},{"key":"285_CR18","doi-asserted-by":"crossref","unstructured":"Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, et al. Effect of hepatic or renal impairment on the pharmacokinetics of Canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37(3):610\u2013628.e4. doi: 10.1016\/j.clinthera.2014.12.013 .","DOI":"10.1016\/j.clinthera.2014.12.013"},{"key":"285_CR19","doi-asserted-by":"crossref","unstructured":"Devineni D, Polidori, D, Curtin, CR, Murphy, J, Wang, SS, Stieltjes, H. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int J Clin Pharmacol Ther. 2015. doi: 10.5414\/CP202324 .","DOI":"10.5414\/CP202324"},{"key":"285_CR20","author":"D Devineni","year":"2014","unstructured":"Devineni D, Murphy J, Wang S-S, Stieltjes H, Rothenberg P, Scheers E, et al. Absolute oral bioavailability and pharmacokinetics of canagliflozin: a microdose study in healthy participants. Clin Pharm Drug Dev. 2014;. doi: 10.1002\/cpdd.162 .","journal-title":"Clin Pharm Drug Dev"},{"key":"285_CR21","author":"D Devineni","year":"2014","unstructured":"Devineni D, Manitpisitkul P, Murphy J, Stieltjes H, Ariyawansa J, Di Prospero N, et al. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clin Pharm Drug Dev. 2014;. doi: 10.1002\/cpdd.151 .","journal-title":"Clin Pharm Drug Dev"},{"issue":"3","key":"285_CR22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5414\/CP202233","volume":"53","author":"J Murphy","year":"2015","unstructured":"Murphy J, Wang SS, Stieltjes H, Wajs E, Devineni D. Effect of food on the pharmacokinetics of canagliflozin\/metformin (150\/1,000\u00a0mg) immediate-release fixed-dose combination tablet in healthy participants. Int J Clin Pharmacol Ther. 2015;53(3):256\u201364.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"285_CR23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/dmd.113.056440","volume":"42","author":"RN Mamidi","year":"2014","unstructured":"Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, et al. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab Dispos. 2014;42(5):903\u201316.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"285_CR24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135.","journal-title":"Pharm Res"},{"issue":"1","key":"285_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425255.2015.982531","volume":"11","author":"S Kinoshita","year":"2015","unstructured":"Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol. 2015;11(1):7\u201314.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"285_CR26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/j.1552-4604.1995.tb04115.x","volume":"35","author":"KM Olsen","year":"1995","unstructured":"Olsen KM, Kearns GL, Kemp SF. Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes. J Clin Pharmacol. 1995;35(7):739\u201345.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"285_CR27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/jps.2600730738","volume":"73","author":"D Mungall","year":"1984","unstructured":"Mungall D, Wong YY, Talbert RL, Crawford MH, Marshall J, Hawkins DW, et al. Plasma protein binding of warfarin: methodological considerations. J Pharm Sci. 1984;73(7):1000\u20131.","journal-title":"J Pharm Sci"},{"issue":"9","key":"285_CR28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1358\/mf.2002.24.9.802312","volume":"24","author":"RF Reinoso","year":"2002","unstructured":"Reinoso RF. Sanchez Navarro A, Garcia MJ, and Prous JR, Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2002;24(9):593\u2013613.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"11","key":"285_CR29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201\u20138.","journal-title":"Drug Metab Dispos"},{"key":"285_CR30","unstructured":"Hoeben E, Vermeulen A, Winter WD, Neyens M, Devineni D, Dunne A. Population pharmacokinetic analysis of canagliflozin, an orally active inhibitor of sodium-glucose co-transporter 2 for the treatment of patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2015 (accepted for publications)."},{"issue":"10","key":"285_CR31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40261-014-0226-x","volume":"34","author":"N Inagaki","year":"2014","unstructured":"Inagaki N, Kondo K, Yoshinari T, Ishii M, Sakai M, Kuki H, et al. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. Clin Drug Investig. 2014;34(10):731\u201342.","journal-title":"Clin Drug Investig"},{"key":"285_CR32","doi-asserted-by":"crossref","unstructured":"Devineni D, Vaccaro N, Polidori D, Curtin CR, Stiltjes H, Hu P, et al. Pharmacokinetics, pharmacodynamics and safety of single-dose canagliflozin in healthy Chinese participants. Clin Ther. 2015 (accepted).","DOI":"10.1016\/j.clinthera.2015.11.008"},{"issue":"5","key":"285_CR33","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","volume":"98","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(5):E867\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"285_CR34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669\u201372.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"285_CR35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","volume":"14","author":"D Devineni","year":"2012","unstructured":"Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, et al. Canagliflozin improves glycaemic control over 28\u00a0days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"285_CR36","doi-asserted-by":"crossref","first-page":"e105638","DOI":"10.1371\/journal.pone.0105638","volume":"9","author":"S Sha","year":"2014","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9(8):e105638.","journal-title":"PLoS One"},{"key":"285_CR37","doi-asserted-by":"crossref","unstructured":"Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(11):1087\u201395. doi: 10.1111\/dom.12322 .","DOI":"10.1111\/dom.12322"},{"issue":"8","key":"285_CR38","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154\u201361.","journal-title":"Diabetes Care"},{"issue":"6","key":"285_CR39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232\u20138.","journal-title":"Diabetes Care"},{"issue":"4","key":"285_CR40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"285_CR41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","volume":"57","author":"D Polidori","year":"2014","unstructured":"Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014;57(5):891\u2013901.","journal-title":"Diabetologia"},{"key":"285_CR42","doi-asserted-by":"crossref","unstructured":"Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 2014;63(10):1296\u2013303. doi: 10.1016\/j.metabol.2014.07.003 .","DOI":"10.1016\/j.metabol.2014.07.003"},{"issue":"2","key":"285_CR43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI115031","volume":"87","author":"BB Kahn","year":"1991","unstructured":"Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest. 1991;87(2):561\u201370.","journal-title":"J Clin Invest"},{"issue":"4","key":"285_CR44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","volume":"80","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80(4):1037\u201344.","journal-title":"J Clin Invest"},{"issue":"5","key":"285_CR45","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","volume":"79","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510\u20135.","journal-title":"J Clin Invest"},{"issue":"12","key":"285_CR46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267\u201382.","journal-title":"Int J Clin Pract"},{"issue":"9896","key":"285_CR47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941\u201350.","journal-title":"Lancet"},{"issue":"3","key":"285_CR48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104\u00a0weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355\u201364.","journal-title":"Diabetes Care"},{"issue":"4","key":"285_CR49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","volume":"65","author":"R Pratley","year":"2011","unstructured":"Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397\u2013407.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"285_CR50","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","volume":"37","author":"BA Perkins","year":"2014","unstructured":"Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480\u20133.","journal-title":"Diabetes Care"},{"issue":"8","key":"285_CR51","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20(8):1645\u201352.","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"285_CR52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","volume":"126","author":"K Usiskin","year":"2014","unstructured":"Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126(3):16\u201334.","journal-title":"Postgrad Med"},{"issue":"7","key":"285_CR53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","volume":"74","author":"G Plosker","year":"2014","unstructured":"Plosker G. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807\u201324.","journal-title":"Drugs"},{"issue":"1","key":"285_CR54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs"},{"issue":"9","key":"285_CR55","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508\u201315.","journal-title":"Diabetes Care"},{"issue":"12","key":"285_CR56","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonzalez","year":"2013","unstructured":"Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582\u201392.","journal-title":"Diabetologia"},{"issue":"5","key":"285_CR57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"285_CR58","unstructured":"Invokana\u2122, Prescribing Information, 2013. Reference ID: 3285059. Drugs@FDA: FDA Approved Drug Products. Original Approval Date March 29, 2013. http:\/\/www.accessdata.fda.gov . Accessed 13 Aug 2014."},{"issue":"8","key":"285_CR59","doi-asserted-by":"crossref","first-page":"e105638","DOI":"10.1371\/journal.pone.0105638","volume":"9","author":"S Sha","year":"2014","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9(8):e105638.","journal-title":"PLoS One"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0285-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0285-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0285-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T03:21:30Z","timestamp":1691724090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0285-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,4]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0285-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,4]]}}}